Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 14/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17370423 | 0.99 | ELANE (0.36) | ELANEKMT2AATMACACBMEN1 | |
| SCHEMBL17370599 | 0.95 | ELANE (0.39) | ELANEKMT2AATMACACBMEN1 | |
| SCHEMBL17370261 | 0.89 | ELANE (0.44) | ELANEKMT2AATMACACBMEN1 | |
| SCHEMBL17370617 | 0.87 | ELANE (0.43) | ELANEKMT2AATMACACBMEN1 | |
| SCHEMBL17370555 | 0.86 | ELANE (0.41) | ELANEKMT2AATMACACBMEN1 | |
| SCHEMBL17370435 | 0.84 | ELANE (0.44) | ELANEKMT2AATMACACBMEN1 | |
| SCHEMBL17370273 | 0.83 | THRB (0.38) | ELANEKMT2AATMACACBAPP | |
| SCHEMBL17370616 | 0.82 | THRB (0.37) | ELANEKMT2AATMACACBAPP | |
| SCHEMBL17370495 | 0.81 | ELANE (0.41) | ELANEKMT2AATMACACBMEN1 | |
| SCHEMBL17370662 | 0.81 | ELANE (0.41) | ELANEKMT2AATMACACBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708534-B2 | Polymerizable compound having triple bond, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9708534-B2 | Polymerizable compound having triple bond, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150376505-A1 | POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150376505-A1 | POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376505-A1 | POLYMERIZABLE COMPOUND HAVING TRIPLE BOND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CCNT1, CCNA1, CCND1 | ELANE 2133/4885KMT2A 3636/4885ATM 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.